Anifrolumab
D3465C00001
Phase 3 small_molecule active
Quick answer
Anifrolumab for Moderate-to-severe Systemic Lupus Erythematosus (SLE) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Moderate-to-severe Systemic Lupus Erythematosus (SLE)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active